koo, I agree.

My guess (pure speculation) is that RVX has been working on a partnership deal for a year and I believe Don thought he would have this wrapped up last Dec/Jan. At the update back then someone asked about the deal and Don sort of off handedly said "it didn't happen". This implies to me that in spite of the scientific advancements and discoveries about apabetalone since the Hepalink deal this next deal, if my hypothesis is correct, is a much more difficult sell. There could be many reasons for this including the price Don is demanding, etc.

Hepalink has the apabetalone rights for China, Taiwan, Macau and regions. They also have a member on the RVX board and a significant share position in RVX. So they weild some power in any decision particularly if it is a regional deal.

I favour a non dilutive partnership deal, hopefully regional and paying royalties back to Zenith Capital. However, if the financing results in dilution it really is not that big of a deal because it creates a buying opportunity. The way I view this business is that the upside with apabetalone only is huge so what does it matter if the share price drops from $1.30 to $0.50 given the potential somewhere between now and and 2022.

However, a new regional deal would be a very strong vote of confidence in apabetalone and potentially other compounds.

I'm just rambling.

GLTA

Toinv